Does pharmacological castration as adjuvant therapy for prostate cancer after radiotherapy affect anxiety and depression levels, cognitive functions and quality of life?

328 Background: Fatigue is commonly reported by patients under anti-angiogenic therapies, with sometimes cognitive complains. However, few studies have explored these problems. A longitudinal multicentric prospective study is ongoing in France on fatigue, cognitive functions, quality of life (QoL), anxiety and depression among metastatic kidney cancer patients receiving anti-angiogenic therapies. Objectives: The main objective is to assess fatigue. Secondary objectives are to assess cognitive functions, QoL, anxiety, and depression. Methods: Assessments are made at baseline, at 3 and 6 months. Evaluations were made by: autoquestionnaire MFI-20 to assess fatigue, FACT-G and FKSI to assess QoL, Spielberger's and Beck's questionnaires to assess respectively anxiety and depression. Cognitive functions were assessed by a neuropsychologist with the Working Memory Index (WAIS-III), Grober and Buschke test, Rey Complexe Figure test, verbal fluency and Trail Making test, exploring respectively working memory, episodic memory and executive functions. Preliminary results are presented. Results: 35 patients were enrolled, and 20 of them had the second assessment at 3 months. Most of patients received sunitinib (51%), others received bevacizumab and interferon, or sorafenib. At baseline, 45% of patients expressed general fatigue and 50% at 3 months (p=0.04). Other domains of fatigue (physical, mental, reduced activity and motivation) did not change over time. At baseline, few patients had cognitive disorders (working memory 6%; executive functions 0%; episodic memory 11%), with no decline at 3 months. However, there was an impairment of QoL in FKSI score (p=0.01) and of FACT-G physical well-being (p=0.01). No differences were found in social, emotional or functional well-being. There was no difference on depression nor on anxiety over time. Conclusions: Fatigue significantly increased during the first 3 months of anti-angiogenic treatment, with no impact on cognitive functions but a decline of QoL. These preliminary findings need to be confirmed by further follow-up and more patients. Final results will be provided with 120 patients. No significant financial relationships to disclose.

Download Full-text

Evaluation of the impact of high-tone therapy on cognitive disorders and quality of life in the complex treatment of patients with comorbid pathology

Balneo and PRM Research Journal ◽

10.12680/balneo.2021.462 ◽

2021 ◽

pp. 345-351

Author(s):

Iryna SHMAKOVA ◽

Svitlana PANINA ◽

Volodymyr MYKHAYLENKO

Keyword(s):

Quality Of Life ◽

Cognitive Functions ◽

Anxiety And Depression ◽

High Tone ◽

Complex Treatment ◽

Group I ◽

Sf 36 ◽

Group Ii ◽

The Impact

Introduction. Comorbidity is an independent risk factor for mortality and significantly influences the prognosis and quality of life. Purpose: to evaluate the impact of high-tone HiTOP 4 touch therapy on cognitive disorders and quality of life in the complex treatment of patients with comorbid pathology. Methods: complex treatment of 2 groups of patients with inclusion in the basic treatment regimen of high-tone therapy was carried out - a total of 80 patients (men - 34, women - 46) aged 41 to 79 years old, group I - patients with hypertension and chronic cerebral ischemia (CСI) - 38 patients and group II - patients with hypertension, CСI and concomitant diabetes mellitus (DM) type 2 - 42 patients. The average age in group I was 61.5, in group II - 65.5. Group I received lisinopril and amlodipine in one tablet, group II received metformin in addition to the above therapy. Both groups received a course of 10 sessions of high-tone therapy using the device HiTOP 4 touch (Germany) according to the general method: 2 electrodes on the feet, 2 on the forearms and one on the neck-collar area. All the patients were assessed for their cognitive condition, degree of anxiety and depression, and estimated for quality of life before and after a course of high-tone therapy. In order to do this, we used valid assessment tests, such as the Montreal Cognitive Assessment Scale (MoCA), the Hospital Anxiety and Depression Scale (HADS), and the SF-36 Quality of Life Questionnaire. Results: the course of high-tone therapy for patients with hypertension and CCI led to improved quality of life, on all indicators of the SF-36 scale, except for pain intensity, increased cognitive functions by 3.52 points on the MoCA scale, reduced anxiety by 2.06 points and depression by 1.92 points on the HADS scale. The course of high-tone therapy for patients with CCI, hypertension and type 2 DM resulted in a significant improvement of 5 out of 8 quality of life indicators on the SF-36 scale, cognitive functions by 2.27 points on the MoCA scale and reduced anxiety by 4.3 points, and depression by 0.53 points on the HADS scale. Conclusion: the inclusion of high-tone therapy in the complex treatment of patients with comorbid pathology improves cognitive functions, reduces anxiety and depression, improves quality of life. Keywords: comorbid pathology, high-tone therapy, cognitive functions, anxiety, depression, quality of life,

Download Full-text

The Relationship between Quality of Life and Cognitive Functions, Anxiety and Depression among Hospitalized Elderly Patients

Clinical Psychopharmacology and Neuroscience ◽

10.9758/cpn.2015.13.2.194 ◽

2015 ◽

Vol 13 (2) ◽

pp. 194-200 ◽

Cited By ~ 18

Author(s):

Özge Saraçlı ◽

Ayşe Semra Demir Akca ◽

Nuray Atasoy ◽

Özde Önder ◽

Ömer Şenormancı ◽

...

Keyword(s):

Quality Of Life ◽

Elderly Patients ◽

Cognitive Functions ◽

Anxiety And Depression ◽

Hospitalized Elderly ◽

Hospitalized Elderly Patients ◽

The Relationship

Download Full-text

Prostate cancer-related quality of life and risk for anxiety and depression.

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.7_suppl.41 ◽

2019 ◽

Vol 37 (7_suppl) ◽

pp. 41-41

Author(s):

Shauna McManus ◽

Julie Olson ◽

Melissa F. Miller ◽

Kelly Clark ◽

Kevin Stein

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Cancer Control ◽

Self Esteem ◽

Anxiety And Depression ◽

Sexual Intimacy ◽

Depression Risk ◽

Clinical Background ◽

Clinically Significant

41 Background: Due to side effects of invasive treatments, prostate cancer (PC) patients face long-term quality of life (QoL) concerns and enduring psychosocial distress. We explored how QoL is linked to distress among a national sample of men with PC. Methods: 214 men with PC enrolled in the Cancer Support Community’s Cancer Experience Registry. Participants provided demographic/clinical background and completed the Prostate Cancer-Related QoL Scales, covering 6 QoL domains ( urinary control, sexual intimacy, sexual confidence, masculine self-esteem, cancer control, and treatment regret). Psychosocial distress was captured by CancerSupportSource, a 25-item tool with 2-item depression and anxiety screening subscales. Scores ≥3 indicate risk for clinically significant depression or anxiety respectively, and signal need for referral and further assessment. We examined bivariate correlations between demographic/clinical background, QoL, and prevalence of ‘risk for clinically significant anxiety and depression’, and used logistic regression to calculate odds of anxiety and depression risk by QoL, adjusting for demographic/clinical variables. Results: Participants were 93% White; mean ( SD) age=64 (12) years; mean ( SD) years since diagnosis=4.3 (4.9); 25% had metastatic disease. 54% underwent radiation; 55% surgery. 40% were at risk for clinically significant anxiety; 35% depression. Poorer QoL scores for sexual intimacy, sexual confidence, masculine self-esteem, cancer control, and treatment regret were bivariately associated with anxiety ( p<.05) and depression ( p<.001) risk. In logistic regression, poorer perceived cancer control predicted anxiety risk (R2=.44; OR=0.97; p<.01). Lower masculine self-esteem predicted depression risk (R2=.68; OR=0.88; p<.05). Conclusions: Questioning treatment efficacy and worrying about disease progression (i.e., lower perceived cancer control) predicts greater likelihood of anxiety risk. Lower masculine self-esteem predicts odds of depression risk. These findings elucidate the ways that PC patients’ perceptions of advancing disease and diminishing masculinity are linked to distress, thus identifying areas for psycho-educational and supportive interventions.

Download Full-text